The TRIUMPH Trial Program Eli Lilly's Phase 3 program includes eight trials spanning multiple conditions
While Wegovy can lead to more weight loss than phentermine, the decision of which medication to use is based on multiple factors that include effectiveness, safety, side effects, affordability, and availability, says Kushner
Medication alone will not solve the obesity crisis, said Tedros
It is found in our lungs, stomach, liver and kidney in high concentration and removes the toxins that enter the body with foods we consume and the air we breathe
Driven by the GLP-1 revolution the extraordinary commercial success of glucagon-like peptide-1 receptor agonist drugs for diabetes and obesity the market was worth USD 84.2 billion in 2025 and is expected to grow at a CAGR of 14.74% to reach USD 196.5 billion by 2031